Patents by Inventor Arshad Siddiqui

Arshad Siddiqui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
    Publication number: 20040116509
    Abstract: The present invention provides novel compounds represented by formula I: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: June 17, 2004
    Applicant: Shire BioChem Inc.
    Inventors: Laval Chan Chun Kong, Jean Bedard, Sanjoy Kumar, Nghe Nguyen Ba, Oswy Z. Pereira, Thumkunta Jagadeeswar Reddy, Mohammad Arshad Siddiqui, Wuyi Wang, Constantin Yannopoulos
  • Compounds and methods for the treatment or prevention of flavivirus infections
    Publication number: 20030229053
    Abstract: the present invention provides novel compounds represented by formula I: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: December 11, 2003
    Applicant: Shire BioChem Inc.
    Inventors: Laval Chan Chun Kong, Jean Bedard, Sanjoy Kumar Das, Nghe Nguyen Ba, Oswy Z. Pereira, Stephen Joseph Shuttleworth, Mohammad Arshad Siddiqui, Wuyi Wang
  • Compounds and methods for the treatment of prevention of flavivirus infections
    Publication number: 20030199503
    Abstract: The present invention provides novel compounds represented by formula I: 1
    Type: Application
    Filed: December 20, 2002
    Publication date: October 23, 2003
    Applicant: Shire BioChem Inc.
    Inventors: Laval Chan Chun Kong, Oswy Z. Pereira, Nghe Nguyen-Ba, Thumkunta Jagadeeswar Reddy, Sanjoy Kumar Das, Mohammad Arshad Siddiqui
  • [1,8] naphthyridine derivatives having antiviral activity
    Patent number: 6605614
    Abstract: The present invention is concerned with novel [1,8] naphthyridine derivatives useful for the inhibition of the hepatitis virus, more specifically the hepatitis C virus.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: August 12, 2003
    Assignee: BioChem Pharma Inc.
    Inventors: Benoit Bachand, Nghe Nguyen-Ba, Arshad Siddiqui, Sophie Levesque
  • [1,8] naphthyridine derivatives having antiviral activity
    Publication number: 20020099072
    Abstract: The present invention is concerned with novel [1,8] naphthyridine derivatives useful for the inhibition of the hepatitis virus, more specifically the hepatitis C virus.
    Type: Application
    Filed: December 27, 2001
    Publication date: July 25, 2002
    Applicant: BioChem Pharma Inc.
    Inventors: Benoit Bachand, Nghe Nguyen-Ba, Arshad Siddiqui, Sophie Levesque
  • Method for the treatment or prevention of flavivirus infections using nucleoside analogues
    Publication number: 20020019363
    Abstract: The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 20, 2001
    Publication date: February 14, 2002
    Inventors: Hicham Moulay Alaoui Ismaili, Yun-Xing Cheng, Jean-Francois Lavallee, Arshad Siddiqui, Richard Storer
  • Antiviral methods using [1,8]naphthyridine derivatives
    Patent number: 6340690
    Abstract: The present invention is concerned with novel [1,8] naphthyridine derivatives useful for the inhibition of the hepatitis virus, more specifically the hepatitis C virus.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: January 22, 2002
    Assignee: Bio-Chem Pharma Inc.
    Inventors: Benoit Bachand, Nghe Nguyen-Ba, Arshad Siddiqui, Sophie Levesque
  • Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors
    Patent number: 6124291
    Abstract: This invention relates to pyrrolo[1,2-a]pyrazine-1,4-diones of general formula: ##STR1## wherein B is carbonyl or methylene, R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen, alkyl, or substituted alkyl, A is a basic group, and Q is hydrogen or a keto heterocycle group.The compounds are inhibitors of serine proteases, typically thrombin, Factor Xa, and Factor VIIa, and are useful for treating and preventing thrombotic disorders.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: September 26, 2000
    Assignee: Warner-Lambert Company
    Inventors: Kent A. Berryman, Annette M. Doherty, Jeremy J. Edmunds, M. Arshad Siddiqui
  • Low molecular weight bicyclic thrombin inhibitors
    Patent number: 6057314
    Abstract: This invention relates to the discovery of heterocyclic competitive inhibitors of the enzyme thrombin, their preparation, and pharmaceutical compositions thereof. As well, this invention relates to the use of such compounds and compositions in vitro as anticoagulants and in vivo as agents for the treatment and prophylaxis of thrombotic disorders such as venous thrombosis, pulmonary embolism and arterial thrombosis resulting in acute ischemic events such as myocardial infarction or cerebral infarction. Moreover, these compounds and compositions have therapeutic utility for the prevention and treatment of coagulopathies associated with coronary bypass operations as well as restenotic events following transluminal angioplasty.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: May 2, 2000
    Assignee: Biochem Pharma Inc.
    Inventors: John Dimaio, M. Arshad Siddiqui, John W. Gillard, Yves St-Denis, Micheline Tarazi, Patrice Preville, Sophie Levesque, Benoit Bachand, Annette Marian Doherty, Jeremy John Edmunds
  • Stereoselective synthesis of nucleoside analogues using bicyclic intermediate
    Patent number: 5763606
    Abstract: The present invention relates to a process for producing predominantly pure cis nucleoside analogues of formula (I), wherein X is S, or O; Y is S, CH.sub.2, O or CH(R); wherein R is azido or halogen; and R.sub.2 is a purine or pyrimidine base; via the coupling of a silylated purine or pyrimidine base in the presence of an appropriate Lewis acid with a bicyclic intermediate of formula (III) wherein Z is S or O; followed by conversion of the resulting intermediate of formula (II) to an alkyl ester and reduction to yield a compound of formula (I).
    Type: Grant
    Filed: February 2, 1995
    Date of Patent: June 9, 1998
    Assignee: BioChem Pharma, Inc.
    Inventors: Tarek S. Mansour, Colleen A. Evans, Haolun Jin, M. Arshad Siddiqui, Allan H. L. Tse
  • Processes for the diastereoselective synthesis of nucleoside analogues
    Patent number: 5696254
    Abstract: The present invention relates to highly diastereoselective processes for production of cis-nucleosides and nucleoside analogues and derivatives in high optical purity, and intermediates useful in those processes.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: December 9, 1997
    Assignee: BioChem Pharma Inc.
    Inventors: Tarek Mansour, Haolun Jin, Allan H. L. Tse, M. Arshad Siddiqui
  • Intermediates in the synthesis of 1,3-oxathiolanyl cytosine nucleoside analogues
    Patent number: 5693787
    Abstract: The present invention relates to highly diastereoselective processes for production of cis-nucleosides and nucleoside analogues and derivatives in high optical purity and intermediates useful in those processes.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 2, 1997
    Assignee: BioChem Pharma Inc.
    Inventors: Tarek Mansour, Haolun Jin, Allan H. L. Tse, M. Arshad Siddiqui
  • Processes for the diastereoselective separation of nucleoside analogue synthetic intermediates
    Patent number: 5663320
    Abstract: The present invention relates to highly diastereoselective processes for production of cis-nucleosides and nucleoside analogues and derivatives in high optical purity and intermediates useful in those processes.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 2, 1997
    Assignee: BioChem Pharma, Inc.
    Inventors: Tarek Mansour, Haolun Jin, Allan H.L. Tse, M. Arshad Siddiqui